46.70

5.34% -2.4161

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $46.70, with a volume of 371.33K. It is down -5.34% in the last 24 hours and down -13.66% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$49.12

Open:

$48.09

24h Volume:

371.33K

Relative Volume:

0.33

Market Cap:

$3.79B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-12.36

EPS:

-3.78

Net Cash Flow:

$-212.64M

1W Performance:

-6.26%

1M Performance:

-13.66%

6M Performance:

+78.90%

1Y Performance:

+67.19%

1-Day Range:

$46.33

$48.78

1-Week Range:

$46.31

$49.66

52-Week Range:

$17.86

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	46.72	3.79B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	490.36	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.30	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	632.13	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.03	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.81	27.34B	3.30B	-501.07M	1.03B	-2.1146

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy
Jan-27-25	Reiterated	H.C. Wainwright	Buy
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

08:57 AM

Akero Therapeutics (NASDAQ:AKRO) Given New $75.00 Price Target at HC Wainwright - MarketBeat

08:57 AM

07:34 AM

Akero Therapeutics stock target raised to $75 by H.C. Wainwright - Investing.com India

07:34 AM

Mar 02, 2025

Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - MSN

Mar 02, 2025

Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025

Akero Therapeutics (NASDAQ:AKRO) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Mar 01, 2025

Feb 28, 2025

Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 28, 2025

Akero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 28, 2025

3 Mid-Caps Worth Watching Closely in March - MarketBeat

Feb 28, 2025

Akero Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025

Akero Therapeutics Q4 Loss Unchanged -February 28, 2025 at 07:27 am EST - Marketscreener.com

Feb 28, 2025

Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Total Operating Expenses $78M - Marketscreener.com

Feb 28, 2025

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian

Feb 28, 2025

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Feb 28, 2025

Can Akero's Breakthrough Cirrhosis Reversal Results Reshape MASH Treatment Landscape? - StockTitan

Feb 28, 2025

IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 28, 2025

Feb 27, 2025

Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? - Insider Monkey

Feb 27, 2025

Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Feb 27, 2025

Feb 26, 2025

Madrigal’s Rezdiffra Continues Its Solid Launch - Citeline News & Insights

Feb 26, 2025

Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN

Feb 26, 2025

Feb 25, 2025

10 Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey

Feb 25, 2025

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 10,000 Shares of Stock - MarketBeat

Feb 25, 2025

Feb 23, 2025